Innofactor Plc: Managers’ Transactions

Innofactor Plc Managers' Transactions, on October 25, 2024, at 9:30 Finnish time

Innofactor Oyj - Managers' Transactions

____________________________________________

Person subject to the notification requirement
Name: Onni Bidco Oy
Position: Closely associated person
(X) Legal person

(1):Person Discharging Managerial Responsibilities In Issuer
Name: Sami Ensio
Position: Chief Executive Officer

(2):Person Discharging Managerial Responsibilities In Issuer
Name: Antti Kummu
Position: Member of the Board

Issuer: Innofactor Oyj
LEI: 7437008OSKQFEDZYD835
Notification type: INITIAL NOTIFICATION
Reference number: 82330/4/4

____________________________________________

Transaction date: 2024-10-24
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009007637
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 1770 Unit price: 1.68 EUR
(2): Volume: 68 Unit price: 1.68 EUR

Aggregated transactions (2):
Volume: 1838 Volume weighted average price: 1.68 EUR

Espoo, October 25, 2024

INNOFACTOR PLC

Eija Theis, General Counsel

Additional information:
Eija Theis, General Counsel
Innofactor Plc
Tel. +358 44 343 4278
[email protected]

Distribution:
NASDAQ Helsinki
Main media
www.innofactor.com

Innofactor
Innofactor is the leading driver of the modern digital organization in the Nordic Countries for its about 1,000 customers in commercial and public sector. Innofactor has the widest solution offering and leading know-how in the Microsoft ecosystem in the Nordics. Innofactor has about 600 enthusiastic and motivated top specialists in Finland, Sweden, Denmark and Norway. The Innofactor Plc share is listed in the technology section of the main list of NASDAQ Helsinki Oy. www.innofactor.com
#ModernDigitalOrganization #PeopleFirst #CreatingSmiles #BeTheRealYou

You May Also Be Interested In

• CREDIT AGRICOLE S.A. ANNOUNCES REDEMPTION OF GBP 750,000,000 Senior Non-Preferred Callable Fixed Rate Resettable Notes issued on November 29, 2022 (ISIN: FR001400E920)*
• Wolters Kluwer 2026 Nine-Month Trading Update
• Breakthrough Therapy Designation granted by the FDA for daridorexant in pediatric insomnia disorder